Patients in the US with ultra-rare blood clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP) have an FDA-approved therapy for the first time, after Tak
Faron Pharmaceuticals has reported data from a phase 1/2 trial pointing to the potential of its macrophage-directed antibody bexmarilimab as a treatment for blood cancers
2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also
UK artificial intelligence (AI) specialist Intelligent Omics has entered into a research collaboration with Johnson & Johnson, within weeks of joining the big pharma's
Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloi